HF
CHRS icon

HRT Financial’s Coherus Oncology CHRS Stock Holding History

HRT Financial’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,527
Closed -$14K – 3893
2025
Q4 		$14K Buy
+10,527
New +$15.3K ﹤0.01% 3023
2025
Q3 		– Sell
-48,778
Closed -$35K – 2930
2025
Q2 		$35K Buy
+48,778
New +$42.1K ﹤0.01% 2349
2024
Q1 		– Sell
-235,077
Closed -$782K – 2395
2023
Q4 		$782K Buy
+235,077
New +$630K 0.01% 1104
2023
Q3 		– Sell
-233,791
Closed -$998K – 2462
2023
Q2 		$998K Buy
+233,791
New +$1.38M 0.01% 954
2022
Q4 		– Sell
-99,287
Closed -$954K – 2534
2022
Q3 		$954K Buy
+99,287
New +$1M 0.01% 963
2022
Q1 		– Sell
-46,731
Closed -$745K – 3180
2021
Q4 		$745K Sell
46,731
-51,269
-52% -$897K ﹤0.01% 1400
2021
Q3 		$1.57M Buy
+98,000
New +$1.44M 0.01% 888
2020
Q4 		– Sell
-24,970
Closed -$457K – 1914
2020
Q3 		$457K Buy
+24,970
New +$465K 0.01% 923

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

HRT Financial's CHRS Position: Q1 2026 in Review

HRT Financial sold out of Coherus Oncology (CHRS) in Q1 2026, closing a stake of 10,527 shares — an estimated $14K sold.

HRT Financial first reported a position in CHRS in Q3 2020 and held it in 8 quarters. The position peaked at $1.57M in Q3 2021. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • HRT Financial reported no remaining Coherus Oncology position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 10,527 Coherus Oncology shares in Q1 2026, an estimated $14K.
  • HRT Financial first reported a position in Coherus Oncology in Q3 2020 and held it in 8 quarters.
  • HRT Financial's Coherus Oncology position peaked at $1.57M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.